MarketVIEW: Meningococcus serogroup B vaccines

• Publication date: January 2012
• Report size: 110 pages

With the introduction of vaccines to prevent invasive meningococcal disease due serogroups ACWY, serogroup B now remains a major contributor to current disease burden, especially in Europe where it accounts for >50% of cases. Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global s...

With the introduction of vaccines to prevent invasive meningococcal disease due serogroups ACWY, serogroup B now remains a major contributor to current disease burden, especially in Europe where it accounts for >50% of cases. Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global scale. Novartis and Pfizer vaccines are currently developing broader acting protein based vaccines, the former (4CmenB) is current undergoing registration in the EMA region. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of new menB vaccines to 2030. The product contains three forecast models (LO, BASE, HI) which examine different adoption scenarios across 40 countries. Detailed coverage of Novartis (4CMenB) and Pfizer (rLP2086) is included with a focus on development history to date and coverage of latest cost effectiveness issues. Other novel menB vaccine approaches are discussed. 

This product is an ideal source of analysis for those wishing to assess the field of new meningococcal vaccines. 

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 3 MODELS 

Biopharmaceutical Industry in Russian Federation

Contents – Executive presentation (MS PowerPoint based)
Author’s note
Executive summary
Commercial model – key outputs
Total available global market to 2030: menB vaccine(s)
menB vaccine: available market (<1 yrs) to 2030
menB vaccine: available market (1-5 yrs) to 2030
menB vaccine: available market (11 - 18 yrs) to 2030
menB vaccine: country adoption groupings (BASE) to 2030
menB vaccine: early adopter MCC countries (BASE) to 2030
menB vaccine: region summary (2018) - base scenario
Novartis Vaccines revenues per scenario to 2030
Pfizer Vaccines revenues per scenario to 2030
Disease background and latest epidemiology
Importance of serogroup B
N. meningitidis dominant serotype(s) per region
N. meningitidis % serotype per region
Global ranking of N. meningitidis (all) incidence
Global ranking of N. meningitidis (serogroup B) incidence
US - N. meningitidis incidence: serogroup distribution by age
US - N. meningitidis incidence: by year 1997 – 2009
Serogroup B: importance of global strains
Importance of meningococcal carriage
Discussion of meningococcal serogroup C vaccination
Case study for serogroup B?
N. meningitidis incidence (EU), 1999 – 2006
N. meningitidis (all) and serogroup C incidence (EU), 1999
Serogroup C vaccination impact on EU incidence: 1999-2006
Serogroup C vaccination impact on incidence – UK
Global Men C conjugate vaccine programs
Global Men A/C conjugate vaccine programs
Global Men ACWY conjugate vaccine programs
Meningococcal serogroup B vaccine: modelling commercial potential
Overall modeling rationale
Serogroup B epidemiology: methodology used
Serogroup B vaccine: rationale for country inclusion
Serogroup B vaccine: Predicted early adopter countries
Serogroup B vaccine: Predicted later adopter countries
Serogroup B vaccine: Predicted limited/or no adoption countries
Serogroup B vaccine: proposed indications
Serogroup B vaccine: modeling methodology
Early adopter countries: vaccine uptake scenarios
All other countries: vaccine uptake scenarios
Coverage level assumptions: 1-5 yrs (early adopters)
Coverage level assumptions: 1-5 yrs (later adopters)
Coverage level assumptions: 11-18 yrs (early adopters)
Coverage level assumptions: 11-18 yrs (later adopters)
Coverage level assumptions: USA (all ages)
UK cost effectiveness analysis: overview
UK cost effectiveness analysis: direct protection model
UK cost effectiveness analysis: alternative strategies
UK cost effectiveness analysis: conclusions
Serogroup B vaccine - pricing scenarios
Serogroup B vaccine – vaccinology and summary of major competitor programs
Timeline of serogroup B vaccine development progress
The challenge of developing a serogroup B vaccine
New Zealand: impact of serogroup B OMV vaccine
Issues with OMV vaccines
A new serogroup B vaccine - which protein antigens?
Surface proteins of Neisseria meningitidis
Review of selected major protein antigens
Focus on Factor H binding protein (fHbp)
4CMenB: Novartis Vaccines - vaccine components
4CMenB: Novartis Vaccines - late development history
4CMenB: Phase III data in infants
4CMenB: summary of late stage development program
4CMenB: coverage prediction UK
Bivalent rLP2086: Pfizer - vaccine components
rLP2086: Pfizer Vaccines - strain pool
Phylogenetic tree of fHBP/LP2086 variants
rLP2086: bactericidal activity
rLP2086: Pfizer Vaccines - development history
rLP2086: Pfizer Vaccines - B1971005
rLP2086: summary of late stage development program (Nov 11)
rLP2086: Pfizer Vaccines - B1971009
Pfizer versus Novartis vaccines approaches
Surrogate markers of protection: key issues and challenges
menB vaccine(s): R&D pipeline / other approaches
Appendix I – back up and source material
UK NHS immunization statistics, England 2010-2011
Bibliography
Disclaimer
About VacZine Analytics
PAGES: 110 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

***NOTE*** - there are 3 models (LO, BASE & Hi scenarios) each with ~ 90 individual sheets
Title sheet
Notes
CHARTS – VAL (pub)
Region summary (2018)
Grand value sum (pub)
Grand volume sum (pub)
Grand vol val (priv)
Country value summary (all ages)
Early adopters 0 – 5 yrs value
Early adopters 11-18 yrs value
Later adopters 0 – 5 yrs value
Later adopters 11-18 yrs value
Global price summary
Early adopters 0 – 5 yrs volume
Early adopters 11-18 yrs volume
Later adopters 0 – 5 yrs volume
Later adopters 11-18 yrs volume
Country worksheets
0 – 5 yrs and 11 – 18 yrs worksheets per country (included for 40 countries)
Country 1
LATAM private
Russia private
Populations =>>
Birth cohorts
Adolescents
Epidemiology =>>
Country men (all) rankings
Country men B rankings
% pub/priv
Back page

Vaccine in Russian Federation

Russia Pharmaceutical Exports - Blood, Antisera, Vaccines, Toxins And Cultures, Us$mn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Russian Federation

Russia Pharmaceutical Imports - Blood, Antisera, Vaccines, Toxins And Cultures, Us$mn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Russian Federation

Russia Pharmaceutical Exports - Blood, Antisera, Vaccines, Toxins And Cultures, Rubmn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Russian Federation

Russia Pharmaceutical Imports - Blood, Antisera, Vaccines, Toxins And Cultures, Rubmn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Russian Federation

Russia Pharmaceutical Exports - Vaccines For Human Use, Us$mn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Drug and Medication
• Countries : Russian Federation